Hans‐jürgen Wester

Hans‐jürgen Wester's AcademicInfluence.com Rankings

Hans‐jürgen Wester

Physics

#5670

World Rank

#7533

Historical Rank

physics Degrees

Hans‐jürgen Wester

Philosophy

#6868

World Rank

#9979

Historical Rank

Logic

#3963

World Rank

#5199

Historical Rank

philosophy Degrees

Download Badge

Physics
Philosophy

Why Is Hans‐jürgen Wester Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hans‐jürgen Wester's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy (2015) (826)
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. (2016) (590)
Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography (2001) (546)
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD (2005) (494)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 (2017) (480)
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. (2001) (409)
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies (2015) (402)
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. (2016) (393)
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy (2016) (372)
O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study (2000) (361)
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting (1999) (355)
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins (2017) (349)
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. (2005) (325)
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. (2004) (306)
Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man (2006) (303)
Exploring the Role of RGD-Recognizing Integrins in Cancer (2017) (281)
Ligands for mapping alphavbeta3-integrin expression in vivo. (2009) (259)
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease (2009) (254)
Biodistribution and Pharmacokinetics of the αvβ3-Selective Tracer 18F-Galacto-RGD in Cancer Patients (2005) (247)
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. (2004) (228)
Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. (2007) (227)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors (2021) (212)
Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [11C]diprenorphine PET study (2004) (211)
An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. (2011) (210)
[18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck (2007) (209)
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease (2008) (199)
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) (2019) (196)
A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. (1996) (196)
Molecular imaging targeting peptide receptors. (2009) (192)
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. (2015) (188)
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. (2001) (188)
PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent (2011) (183)
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. (2009) (181)
Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. (2004) (179)
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. (2006) (178)
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. (2019) (173)
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT (2016) (173)
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma (2015) (170)
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma (2007) (164)
SPECT-CT (2008) (164)
High opiate receptor binding potential in the human lateral pain system (2006) (163)
Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG (2007) (163)
Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study (2007) (161)
PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide (2002) (161)
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease (2016) (161)
Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. (2015) (159)
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. (2016) (157)
Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET (2008) (157)
Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer (2006) (156)
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging (2015) (155)
Evaluation of &agr;v&bgr;3 Integrin-Targeted Positron Emission Tomography Tracer 18F-Galacto-RGD for Imaging of Vascular Inflammation in Atherosclerotic Mice (2009) (154)
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT (2008) (148)
Initial Characterization of an 18F-Labeled Myocardial Perfusion Tracer (2008) (146)
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013 (2016) (143)
PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand (2011) (143)
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer (2017) (143)
TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. (2011) (141)
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. (2006) (141)
PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis. (2014) (139)
O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes (2002) (138)
68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression (2008) (138)
99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. (2019) (138)
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer (2014) (137)
Phantom limb pain in the human brain: Unraveling neural circuitries of phantom limb sensations using positron emission tomography (2000) (132)
Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy (2015) (132)
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature (2018) (130)
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. (1999) (127)
Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions (2017) (127)
18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression (2010) (126)
Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis (2007) (126)
68 Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (123)
PET Imaging of Integrin αVβ3 Expression (2011) (120)
Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. (2008) (118)
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. (2006) (117)
Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease (2012) (115)
The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration (2011) (114)
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values (2017) (111)
CXCR4 Ligands: The Next Big Hit? (2017) (107)
Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer (2017) (107)
Carbohydrate Derivatives for Use in Drug Design: Cyclicαv-Selective RGD Peptides (2000) (106)
Opioidergic activation in the medial pain system after heat pain (2006) (106)
Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay (2012) (105)
Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. (2005) (105)
Nuclear Imaging Probes: from Bench to Bedside (2007) (105)
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET (2012) (105)
Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe 68Ga-Pentixafor (2015) (101)
Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (101)
First Experience with Chemokine Receptor CXCR4–Targeted PET Imaging of Patients with Solid Cancers (2016) (97)
Clinical severity of Alzheimer's disease is associated with PIB uptake in PET (2009) (96)
First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography (2004) (96)
Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. (2002) (95)
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent (2016) (93)
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. (2011) (93)
Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. (2007) (92)
Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden (2017) (92)
Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer 68Ga-Pentixafor for PET (2017) (90)
Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus (2008) (89)
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. (2019) (88)
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience (2016) (87)
Cationic eluate pretreatment for automated synthesis of [⁶⁸Ga]CPCR4.2. (2014) (85)
(2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. (1994) (84)
Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation (2004) (84)
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy (2016) (84)
[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery (2015) (84)
Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. (2013) (81)
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma (2017) (78)
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma (2016) (78)
CXCR4-directed theranostics in oncology and inflammation (2018) (77)
Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. (2019) (74)
Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. (2009) (74)
Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. (2006) (73)
Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. (1999) (73)
Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment (2011) (72)
Metabolically stabilized benzothiazoles for imaging of amyloid plaques. (2007) (72)
68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging (2016) (72)
Molecular Imaging of Early αvβ3 Integrin Expression Predicts Long-Term Left-Ventricle Remodeling After Myocardial Infarction in Rats (2012) (71)
Consensus on molecular imaging and theranostics in prostate cancer. (2018) (70)
One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). (2010) (70)
Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response (2008) (69)
Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer (2016) (69)
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? (2005) (69)
Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas (2015) (69)
Value of 111In‐prostate‐specific membrane antigen (PSMA)‐radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow‐up (2017) (69)
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine (2008) (68)
68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer (2015) (68)
Opioidergic changes in the pineal gland and hypothalamus in cluster headache: A ligand PET study (2006) (67)
Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer (2018) (66)
How is 68Ga Labeling of Macrocyclic Chelators Influenced by Metal Ion Contaminants in 68Ge/68Ga Generator Eluates? (2013) (66)
Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria (2017) (65)
Radiotracer-based strategies to image angiogenesis. (2003) (65)
[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent (2017) (65)
Opioid receptors in the human cerebellum: evidence from [11C]diprenorphine PET, mRNA expression and autoradiography. (1999) (64)
Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in 11C-Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer (2011) (64)
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach (2017) (64)
[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques (2017) (63)
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. (2019) (63)
High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation (2014) (62)
Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer (2017) (62)
Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease. (2011) (62)
A New 18F-Labeled Myocardial PET Tracer: Myocardial Uptake After Permanent and Transient Coronary Occlusion in Rats (2008) (62)
3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides. (2007) (62)
18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK) (2009) (62)
Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals. (2018) (60)
Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC (2017) (60)
Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. (2007) (60)
Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer (2011) (60)
Evaluation of a Novel 18F-Labeled Positron-Emission Tomography Perfusion Tracer for the Assessment of Myocardial Infarct Size in Rats (2009) (58)
High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes (2012) (58)
[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. (2008) (57)
Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT (2018) (57)
Imaging of Proliferation in Hepatocellular Carcinoma with the In Vivo Marker 18F-Fluorothymidine (2009) (56)
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications (2014) (56)
Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography (2008) (56)
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine. (2009) (54)
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics (2018) (54)
Oxalic acid supported Si-18F-radiofluorination: one-step radiosynthesis of N-succinimidyl 3-(di-tert-butyl[18F]fluorosilyl)benzoate ([18F]SiFB) for protein labeling. (2012) (52)
Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. (2019) (51)
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients (2017) (51)
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma (2018) (50)
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia (2016) (50)
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction (2013) (50)
Fluorescence guided surgery and tracer-dose, fact or fiction? (2016) (49)
[(68)Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction. (2015) (49)
Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors (2019) (49)
A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. (2012) (49)
Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics (2001) (49)
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques. (2011) (48)
18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy (2019) (47)
Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). (2014) (47)
Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer’s disease (2012) (46)
68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer (2016) (46)
Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI (2016) (46)
Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, αvβ3 Expression, and Glucose Metabolism (2010) (46)
6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. (2000) (46)
Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours? (2011) (46)
Fast and repetitive in-capillary production of [18F]FDG (2009) (45)
Cryptate mediated nucleophilic 18F-fluorination without azeotropic drying (2011) (45)
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma (2019) (45)
Tailored Gallium(III) chelator NOPO: synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging. (2014) (43)
[68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery (2019) (43)
In Vivo PET Imaging of the Cancer Integrin αvβ6 Using 68Ga-Labeled Cyclic RGD Nonapeptides (2017) (42)
Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance (2019) (42)
Tailoring Fluorescent Dyes To Optimize a Hybrid RGD-Tracer. (2016) (42)
Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. (2020) (42)
Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging (2016) (42)
Chemoselective hydrazone formation between HYNIC-functionalized peptides and (18)F-fluorinated aldehydes. (2006) (42)
Ligands for Mapping a v 3 -Integrin Expression in Vivo (2009) (41)
A Monoreactive Bifunctional Triazacyclononane Phosphinate Chelator with High Selectivity for Gallium‐68 (2012) (41)
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner (2012) (41)
Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography (2008) (41)
213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. (2017) (41)
18F-FDG PET Detects Inflammatory Infiltrates in Spinal Cord Experimental Autoimmune Encephalomyelitis Lesions (2012) (41)
Imaging of C-X-C Motif Chemokine Receptor CXCR4 Expression After Myocardial Infarction With [68Ga]Pentixafor-PET/CT in Correlation With Cardiac MRI. (2018) (41)
89Zr-Labeled Versus 124I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo (2015) (40)
Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry. (2005) (39)
In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors (2008) (38)
Chemokine receptor - Directed imaging and therapy. (2017) (38)
A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. (2015) (37)
Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. (2013) (37)
Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment (2008) (37)
Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer (2016) (36)
Non-invasive imaging of glycoprotein VI binding to injured arterial lesions (2005) (36)
Twins in spirit - episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE (2015) (36)
Imaging Inflammation in Atherosclerosis with CXCR4-Directed 68Ga-Pentixafor PET/CT: Correlation with 18F-FDG PET/CT (2019) (36)
Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. (2008) (35)
Evaluation of cardiac beta-adrenoreceptors in the isolated perfused rat heart using (S)-11C-CGP12388. (2004) (35)
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results (2018) (35)
Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye–Protein Interaction (2020) (35)
68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer (2017) (35)
Modeling and Predicting Tumor Response in Radioligand Therapy (2019) (34)
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. (2004) (34)
Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers? (2019) (34)
A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugates. (2013) (33)
Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007 (2018) (33)
Diet intervention reduces uptake of αvβ3 integrin-targeted PET tracer 18F-galacto-RGD in mouse atherosclerotic plaques (2012) (33)
Radiolabeled carbohydrated somatostatin analogs: a review of the current status. (2004) (32)
A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma (2011) (32)
Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis (2015) (32)
Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI (2019) (31)
Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation (2017) (30)
Molecular Imaging in Oncology Using Positron Emission Tomography. (2018) (30)
Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity (2020) (30)
Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. (2003) (30)
Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. (2005) (30)
Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer (2019) (30)
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice (2015) (29)
Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin (2016) (29)
The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity (2016) (29)
CXCR4-Directed Imaging in Solid Tumors (2019) (29)
Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals (2019) (28)
A Practical Guide on the Synthesis of Metal Chelates for Molecular Imaging and Therapy by Means of Click Chemistry. (2016) (28)
Molar Activity of Ga-68 Labeled PSMA Inhibitor Conjugates Determines PET Imaging Results. (2018) (28)
How Many PET Tracers Do We Need? (2011) (28)
68Ga-Pentixafor PET/CT Imaging of Chemokine Receptor CXCR4 in Chronic Infection of the Bone: First Insights (2017) (28)
Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer (2019) (28)
Positron emission tomography as a tool for translational research in oncology. (2004) (28)
Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates (2012) (28)
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL (2014) (27)
18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. (2015) (27)
Proof of principle for the use of 11C-labelled peptides in tumour diagnosis with PET (2004) (27)
Copper-64 labelling of triazacyclononane-triphosphinate chelators. (2012) (27)
Side Effects of CXC-Chemokine Receptor 4–Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation (2019) (27)
Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide. (2019) (27)
N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. (2005) (27)
Positron emission tomography/magnetic resonance imaging with 68Gallium‐labeled ligand of prostate‐specific membrane antigen: Promising novel option in prostate cancer imaging? (2014) (26)
Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine. (2006) (26)
CXCR4 Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma (2017) (26)
[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model (2008) (26)
Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA (2003) (25)
Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. (2004) (25)
68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer (2016) (25)
First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo (2016) (25)
Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer (2018) (25)
Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity (2018) (24)
Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy (2019) (24)
68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. (2017) (24)
Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T (2018) (24)
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma (2020) (24)
PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma (2018) (23)
Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities (2017) (23)
Convenient synthesis of (68)Ga-labeled gadolinium(III) complexes: towards bimodal responsive probes for functional imaging with PET/MRI. (2013) (23)
Imaging of angiogenesis in cardiology (2007) (23)
From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies. (2019) (23)
In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models (2018) (22)
From a Helix to a Small Cycle: Metadynamics-Inspired αvβ6 Integrin Selective Ligands. (2018) (22)
Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions (2017) (22)
Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins α5β1 and αvβ3 (2016) (22)
PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. (2016) (21)
Volumetric Analysis of F-18-FET-PET Imaging for Brain Metastases. (2015) (21)
Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor. (2006) (21)
Prostate-Specific Membrane Antigen–Guided Surgery (2019) (20)
Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy (2017) (20)
Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience (2014) (20)
Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET (2016) (20)
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT (2021) (20)
Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer (2019) (19)
Carbon-11 labelling of an N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging (2003) (19)
In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366 (2016) (19)
A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency (2020) (18)
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model (2019) (18)
Preferred transport of O-(2-[18F]fluoroethyl)-d-tyrosine (d-FET) into the porcine brain (2007) (18)
Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand. (2015) (18)
Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin αvβ3 expression and myocardial blood flow (2020) (18)
Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy (2017) (18)
Synthesis and evaluation of a full-agonist orvinol for PET-imaging of opioid receptors: [11C]PEO. (2009) (18)
Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6 (2018) (18)
68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant (2017) (17)
Myocardial Kinetics of a Novel [(18)F]-Labeled Sympathetic Nerve PET Tracer LMI1195 in the Isolated Perfused Rabbit Heart. (2015) (16)
PET/CT with Gluc-Lys-([18F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions (2008) (16)
Development and first in human evaluation of PSMA I&T - A ligand for diagnostic imaging and endoradiotherapy of prostate cancer (2014) (16)
The Influence of the Combination of Carboxylate and Phosphinate Pendant Arms in 1,4,7-Triazacyclononane-Based Chelators on Their 68Ga Labelling Properties (2015) (16)
Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics (2018) (16)
Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics (2007) (15)
CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET (2021) (15)
Fully Automated 89Zr Labeling and Purification of Antibodies (2018) (15)
Synthesis of a [18F]fluorobenzothiazole as potential amyloid imaging agent (2008) (15)
Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer (2016) (14)
Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival (2013) (14)
Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics (2020) (14)
At the Bench: Pre‐clinical evidence for multiple functions of CXCR4 in cancer (2020) (14)
Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (14)
N-Methylation of isoDGR Peptides: Discovery of a Selective α5β1-Integrin Ligand as a Potent Tumor Imaging Agent. (2018) (14)
Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion (2016) (14)
Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [68Ga]pentixafor (2016) (14)
Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? (2021) (14)
Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors (2017) (14)
A facile direct nucleophilic synthesis of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) without HPLC purification (2014) (14)
Dendritic poly-chelator frameworks for multimeric bioconjugation. (2017) (13)
Synthesis, biological evaluation and radiolabelling by 18F-fluoroarylation of a dopamine D3-selective ligand as prospective imaging probe for PET. (2010) (13)
A New Method for Radiosynthesis of 11C-Labeled Carbamate Groups and its Application for a Highly Efficient Synthesis of the Kappa-Opioid Receptor Tracer [11C]GR103545 (2008) (13)
[68Ga]Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke. (2016) (13)
Targeting CXCR 4 ( CXC Chemokine Receptor Type 4 ) for Molecular Imaging of Aldosterone-Producing Adenoma (13)
Orthogonally protected artificial amino acid as tripod ligand for automated peptide synthesis and labeling with [(99m)Tc(OH(2))(3)(CO)(3)](+). (2013) (13)
Prospective evaluation of PSMA-PET imaging for preoperative lymph node staging in prostate cancer (2014) (12)
Gender dependent rate of metabolism of the opioid receptor-PET ligand [18F]fluoroethyldiprenorphine (2005) (12)
Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III. (2014) (12)
Mapping the Binding Interface of PET Tracer Molecules and Alzheimer Disease Aβ Fibrils by Using MAS Solid‐State NMR Spectroscopy (2020) (11)
CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication (2021) (11)
[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas (2019) (11)
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas (2021) (11)
Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization (2016) (11)
18F-labeled sufentanil for PET-imaging of mu-opioid receptors. (2005) (11)
A Practical Guide on the Synthesis of Metal Chelates for Molecular Imaging and Therapy by Means of Click Chemistry (2016) (11)
Twins in spirit: DOTATATE and high-affinity DOTATATE (2013) (11)
Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma. (2017) (11)
An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides (2015) (11)
42 18 F: Labeling Chemistry and Labeled Compounds (2011) (10)
Development of an improved radioiodinated 2-phenylimidazo[1,2-a]pyridine for non-invasive imaging of amyloid plaques (2012) (10)
First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer (2014) (10)
The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma (2017) (10)
Peptides, multimers and polymers. (2008) (10)
Radiochemical 18F-fluoroarylation of unsaturated α-, β- and γ-amino acids, application to a radiolabelled analogue of baclofen (2008) (10)
Synthesis of [18F]fluoroalkyl esters of carfentanil (2005) (10)
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T (2020) (10)
Functional Imaging of Pheochromocytoma with 68Ga-DOTATOC and 68C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia (2011) (10)
Anti-Inflammatory Effects on Atherosclerotic Lesions Induced by CXCR4-Directed Endoradiotherapy. (2018) (10)
Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in IPF. (2020) (10)
Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions (2021) (9)
Chemokine Receptor 4 Expression in Primary Sjögren's Syndrome. (2018) (9)
Effect of Carbohydration on the Theranostic Tracer PSMA I&T (2018) (9)
PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with 68Ga-HBED-PSMA. (2015) (9)
[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model (2017) (8)
Recent development and potential use of µ‐ and κ‐opioid receptor ligands in positron emission tomography studies (2006) (8)
First Experience on Chemokine Receptor CXCR4 Targeted Positron Emission Tomography (PET) Imaging in Patients with Solid Cancers (2016) (8)
Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo (2019) (8)
Equilibrium Thermodynamics, Formation, and Dissociation Kinetics of Trivalent Iron and Gallium Complexes of Triazacyclononane-Triphosphinate (TRAP) Chelators: Unraveling the Foundations of Highly Selective Ga-68 Labeling (2018) (8)
Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer (2021) (8)
Molecular Imaging of Inflammation and Fibrosis in Pressure Overload Heart Failure (2021) (8)
Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment (2018) (8)
Radio-analytical determination of the coating efficiency of cyclic RGD peptides (2006) (8)
[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model]. (2013) (7)
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients (2021) (7)
Dimer formation of GdDO3A-arylsulfonamide complexes causes loss of pH-dependency of relaxivity. (2017) (7)
Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. (2017) (7)
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer – a first clinical approach (2021) (7)
Integrin {alpha}v{beta}3 expression and glucose metabolism do not correlate in primary and metastatic lesions in cancer patients: A PET study using [18F]Galacto-RGD and [18F]FDG (2007) (7)
Targeting Chemokine Receptor CXCR4 and Translocator Protein for Characterization of High-Risk Plaque in Carotid Stenosis Ex Vivo (2018) (7)
Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging (2017) (7)
Click Chemistry in the Design and Production of Hybrid Tracers (2019) (7)
18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases (2018) (7)
[111In]DOTATOC as a dosimetric substitute for kidney dosimetry during [90Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach (2006) (6)
Synthesis of Symmetrical Tetrameric Conjugates of the Radiolanthanide Chelator DOTPI for Application in Endoradiotherapy by Means of Click Chemistry (2018) (6)
Radical fluoroarylation in radiochemical synthesis (2008) (6)
Therapy of Metastasized Castrate-Resistant Prostate Cancer Using Lu-177 Labeled DOTAGA-PSMA Small Molecules: First Clinical Results in a Larger Patient Cohort (2015) (6)
Multiparametric Labeling Optimization and Synthesis of 68Ga-Labeled Compounds Applying a Continuous-Flow Microfluidic Methodology (2016) (6)
Radiosynthesis and pre-clinical evaluation of [68Ga] labeled antimicrobial peptide fragment GF-17 as a potential infection imaging PET radiotracer. (2019) (6)
Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer (2018) (6)
Dosimetric measurements of 68Ga-High Affinity DOTATATE (2014) (6)
Biodistribution and radiation dosimetry in healthy volunteers of a novel tumour-specific probe for PET/CT imaging: BAY 85-8050 (2013) (6)
Biokinetics and Dosimetry of 177Lu-Pentixather (2021) (6)
[68Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging (2020) (6)
Twins in spirit - episode I: comparative preclinical evaluation of ( 68 Ga)DOTATATE and (2015) (6)
217 PSMA-PET/MRI-guided transrectal fusion biopsy for the detection of prostate cancer (2015) (6)
68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms (2021) (6)
CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma (2019) (6)
CXCR4 chemokine receptor SPECT/PET imaging with radiolabeled CPCR4: A promising approach for imaging metastatic processes (2006) (6)
Preclinical evaluation of [ 68 Ga ] NOTA-pentixafor for PET imaging of CXCR 4 expression in vivo — a comparison to [ 68 Ga ] pentixafor (2016) (6)
From interventionist imaging to intraoperative guidance: New perspectives by combining advanced tools and navigation with radio-guided surgery. (2018) (5)
PD32-07 PREOPERATIVE LYMPH NODE STAGING IN INTERMEDIATE TO HIGH-RISK PROSTATE CANCER PATIENTS USING 68GA-HBED-PSMA PET HYBRID IMAGING – A PATIENT- AND FIELD-BASED ANALYSIS (2015) (5)
Comparison of [11C]Choline ([11C]CHO) and [18F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model (2016) (5)
Visualization of Posttraumatic Splenosis on Chemokine Receptor CXCR4-Targeted PET/CT. (2017) (5)
The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data (2021) (5)
CXCR4 receptor targeting for in-vivo imaging of metastases (2008) (5)
[68Ga]-NODAGA-RGD Positron Emission Tomography (PET) for Assessment of Post Myocardial Infarction Angiogenesis as a Predictor for Left Ventricular Remodeling in Mice after Cardiac Stem Cell Therapy (2020) (5)
Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT (2018) (5)
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy. (2015) (5)
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy (2021) (5)
[68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model – comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression (2017) (5)
Assessment of a v b 3 integrin expression after myocardial infarction by positron emission tomography (2008) (5)
First in vivo data of [111In]maltose-Lys0(DOTA)-Tyr3-octreotide indicate a high potential of glycated, radiometalated octreotide derivatives for diagnosis and therapy (2000) (4)
Twins in spirit part IV – [177Lu] high affinity DOTATATE (2017) (4)
Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma? (2017) (4)
[11C]choline as a pharmacodynamic marker for docetaxel therapy (2013) (4)
Strategies for Radioligand Development (1998) (4)
Erratum to: Twins in spirit: DOTATATE and high-affinity DOTATATE (2014) (4)
From interventionist imaging to intraoperative guidance: New perspectives by combining advanced tools and navigation with radio-guided surgery (2018) (3)
Pentixafor – Positron Emission Tomography / Computed Tomography Detects Chemokine Receptor CXCR 4 Expression After Ischemic Stroke (2016) (3)
Production of clinical radiopharmaceuticals: general pharmaceutical and radioanalytical aspects (2017) (3)
Nuclear medicine 2013: from status quo to status go (2013) (3)
[GMP production.Shaping the future]. (2012) (2)
Feasibility of in vivo amyloid plaque imaging in a transgenic mouse model of Alzheimer's disease (2007) (2)
Radioligand therapy with Lutetium 177-labeled PSMA-I&T for metastatic castration-resistant prostate cancer: Clinical experience with 100 consecutive patients (2018) (2)
Synthesis of DOTA conjugated GF-17 and RAWVAWR-NH2 and radiolabeling with 68Ga as a potential PET tracer for infection imaging (2016) (2)
Glycation of radioiodinated octreotates increases renal excretion and tumor uptake (2000) (2)
Evaluation of asymmetric orthogonal cyanine fluorophores (2020) (2)
Imaging of integrin {alpha}{nu}{beta}3 expression: A comparative study using [18F]Galacto-RGD and [68Ga]NODAGA-RGD (2011) (2)
Novel compounds for specific visualization of alpha-synucleinopathies by PET (2016) (2)
Detection rate for a novel 68Ga-PSMA PET-ligand in patients with biochemical recurrence of prostate cancer using PET/CT and PET/MR imaging (2014) (2)
Peptide-Receptor Radiotherapy with CXCR4-Targeting Pentixather Reduces Leukemia Burden in Acute Leukemia PDX and Patients (2016) (2)
CXCR4-targeted imaging of leukocyte mobilization after myocardial infarction (2018) (2)
MP42-08 STAGING OF INTERMEDIATE AND HIGH-RISK PROSTATE CANCER USING WHOLE BODY 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/MRI (2014) (2)
Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard (2020) (2)
Imaging of CXCR4 chemokine receptor expression with [68Ga]pentixafor: First experience in cancer patients (2014) (2)
Biodistribution and dosimetry of Lu-177 PSMA in metastasized castrate resistant prostate cancer patients (2014) (2)
[68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma (2014) (2)
PET/MRI/TRUS image fusion guided prostate biopsy: development of a research platform and initial clinical results (2015) (2)
Comparison of [11C]Choline ([11C]CHO) and S(+)-β-Methyl-[11C]Choline ([11C]SMC) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model (2015) (2)
Targeting of αvβ3 integrins using cyclic RGD-peptides labeled with [123/131I]iodine, [18F]fluorine, [99mTc]technetium, [188Re]rhenium and [88/90Y]yttrium (2000) (2)
[18F]BAY 85-8050 (TIM-1): A novel tumor specific probe for PET/CT imaging - First clinical results (2010) (2)
726 68Gallium-labelled ligand of prostate-specific membrane antigen (PSMA) for the evaluation of recurrent prostate cancer using PET/CT and PET/MR imaging (2014) (1)
Imaging of {alpha}v{beta}3 expression and glucose metabolism in melanoma xenografts with PET and correlation with gene expression (2011) (1)
EANM’16 (2016) (1)
Freehand SPECT for 111In-PSMA-I&T radioguided lymphadenectomy in prostate cancer patients (2015) (1)
Taking Ga-68 labeling optimization to the fast line with a new microfluidic system (2014) (1)
68Ga-Radiopharmaka: Methode oder Episode? (2018) (1)
First in man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled Pentixather in multiple myeloma patients (2015) (1)
Oral Presentations_Tuesday (2009) (1)
213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer (2016) (1)
PD32-06 DETECTION RATES OF 68GALLIUM-LABELLED LIGAND OF PSMA PET/CT AND PET/MRI IN 332 CONSECUTIVE PATIENTS WITH BIOCHEMICAL RECURRENCY AFTER RADICAL PROSTATECTOMY (2015) (1)
[18F]BAY 85-8050 (TIM-1): A novel tumor specific probe for PET/CT imaging - Dosimetry (2010) (1)
Imaging of proliferation in hepatocellular carcinoma (HCC) with the in-vivo marker FLT (2009) (1)
Change of tumor cell proliferation during R-CHOP chemotherapy of diffuse large B cell lymphoma (DLBCL) measured by 18FLT-PET (2006) (1)
928 Contribution of PSMA-PET compared to morphological imaging with regard to detection rate in prostate cancer patients with biochemical recurrence after radical prostatectomy (2015) (1)
Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents? (2021) (1)
[68Ga]DOTA-RGD for the non-invasive determination of the αvβ3 integrin expression (2006) (1)
Preclinical results of novel GRPR-targeted antagonists with modified binding sequences (2020) (1)
18F-rhPSMA7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy (2019) (1)
P1-247: Clinical severity of Alzheimer's disease is associated with PIB uptake in PET (2008) (1)
Abstract 2945: Assessment of Transient Myocardial Alpha(v)beta(3) Integrin Expression after Ischemia by PET (2007) (1)
Clinical Molecular Imaging of the Chemokine Receptor CXCR4 in Idiopathic Pulmonary Fibrosis using 68Ga-Pentixafor PET/CT (2016) (1)
Detection of locally advanced gastric cancer with Fluoro-18-thymidine and Fluoro-18-fluorodeoxyglucose positron emission tomography (2007) (1)
Regional expansion of hypometabolism and amyloid deposition in AD and their relation to functional connectivity networks in healthy controls (2011) (1)
F-18 Galacto-RGD PET to determine myocardial integrin expression following ischemia-reperfusion in a rat model (2006) (1)
Carbohydrated TC-99M- and F-18-labelled octreotide derivatives for spect and pet: Synthesis, radiolabelling and first in vivo data (2001) (1)
558 Diagnostic efficacy of 68Ga-PSMA PET for lymph node staging and metastatic distribution in patients with intermediate to high-risk prostate cancer (2016) (1)
Preparation and assessment of F-18 fluorogas for lung scintigraphy (2011) (1)
Back Cover: Selective Imaging of the Angiogenic Relevant Integrins α5β1 and αvβ3 (Angew. Chem. Int. Ed. 44/2013) (2013) (1)
Preparation of highly reactive [18F]fluoride without any evaporation step (2011) (1)
438 PSMA-radioguided surgery for recurrent prostate cancer - mid-term follow-up and novel developments (2016) (1)
557 Localization of primary prostate cancer by simultaneous 68Gallium-HBED-CC-PSMA PET and multiparametric MRI (2016) (1)
Multi-tracer molecular imaging reveals critical role of macrophages for cardiac repair after acute myocardial infarction (2020) (1)
CXCR4 Labels Immune Cells in Esophageal Adenocarcinoma and Could Serve as a Pet Tracer for Diagnostics and to Monitor Therapy Response (2017) (0)
Role of Ga-68 PSMA PET/CT in Theranostics of Metastasized Prostate Cancer (2015) (0)
Simple and fast {sup 18}F-labeling of proteins by coupling with photogenerated [{sup 18}F] arylnitrene (1994) (0)
C O N T I N U I N G E D U C a T I O N Spect/ct* (2008) (0)
Characterization of {alpha}v{beta}3 integrin directed molecular imaging and histopathological correlation in infarcted rat myocardium (2012) (0)
P2-338 Assessment of cerebral hypometabolism and amyloid plaque load in semantic dementia and dementia of the Alzheimer type (2006) (0)
Evaluation of 68Ga-labeled RGD peptides for {alpha}v{beta}3 integrin detection in myocardial infarct (2012) (0)
Comparison of [11C]Choline and [18F]Galacto-RGD as pharmacodynamic biomarker for therapy response assessment of avastin therapy in a PC-3 Prostate Cancer Xenograft Model (2015) (0)
675 Introduction of PSMA-radioguided surgery in patients with recurrent prostate cancer: Taking salvage lymphadenectomy to the next level? (2015) (0)
Outcomes of PSMA-radioguided surgery in recurrent prostate cancer (2016) (0)
Abstract 15086: Early 18F-galacto-RGD Uptake and Left Ventricular Remodeling in a Rat Model of Myocardial Infarction (2010) (0)
O-(2-(F-18)fluorethyl)-L-tyrosin: A practicable aminoacid tracer for tumour volume definition by means of positron-emission-tomography in ZNS tumours (2005) (0)
Evaluation of 3-deoxy-3-18fluorothymidine PET (FLT-PET) for the detection of pancreatic cancer - Comparison to FDG-PET/CT (2009) (0)
Current developments of 18F-labeled PET tracers in oncology (2000) (0)
In-vivo proliferation imaging for early response assessment in patients with aggressive non-Hodgkins lymphoma (2011) (0)
Prefrontal hypometabolism in Alzheimer’s disease is caused by longitudinal amyloid accumulation in remote, functionally connected brain regions (2013) (0)
MP42-18 IMAGING OF RECURRENT PROSTATE CANCER USING 68GALLIUM-LABELLED LIGAND OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT AND PET/MRI (2014) (0)
PD17-04 DIAGNOSTIC EFFICACY OF 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR N-STAGING OF PATIENTS WITH HIGH RISK PRIMARY PROSTATE CANCER (2019) (0)
DRUG-SPECIFIC MODULATION OF 11C-CHOLIN UPTAKE IN HUMAN PROSTATE CANCER CELL LINES (2006) (0)
Society communications (2008) (0)
High contrast in vivo imaging of CD20 and HER2 with Fab fragments engineered for extended plasma half-life (2012) (0)
Synthesis, conjugation of GF-17 and RAWVAWR-NH2 with DOTA and radiolabeling with Gallium-68 (2016) (0)
Surgery in Motion Technetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer (2015) (0)
769 Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer (2016) (0)
Extramedullary Relapsed Multiple Myeloma Treatment With 177Lu-Labeled CXCR4 Endoradiotherapy and Dosimetric Results. (2021) (0)
Molecular imaging of CXCR4 expression in extensive stage small cell lung carcinoma using PET/CT (2014) (0)
Cellular and fluorescence localization of 18F Galacto-RGD in a rat model of myocardial infarction (2009) (0)
Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
A novel fast 18F-labeled octreotide analogue: First PET experience, with n alpha-(1-deoxy-D-fructosyl)-N epsilon-(2-fluoropropionyl)-Lys0-Tyr3-octreotate (FP-Gluc-TOCA). (2003) (0)
Abstract 587: Diet Intervention Reduces 18F-galacto-RGD Uptake in Mouse Atherosclerotic Plaques (2009) (0)
Characterization of [F-18]FIBT, a highly selective and specific PET imaging agent for beta-amyloid plaques (2013) (0)
A-B. Scatter plot of the correlations of ADC and 18 F-FDG uptake (B). (2015) (0)
PSMA I&T for radionuclide imaging and therapy of prostate cancer: preclinical implications of blocking renal uptake with 2-PMPA (2016) (0)
A 68Ga-labelled PET probe for selective imaging of αvβ8-integrin (2019) (0)
Characterizing the optimal acquisition duration of [18F]fluoroethyl-diprenorphine PET studies (2005) (0)
Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrent prostate cancer (2020) (0)
Synthesis and characterization of antimicrobial peptide fragment derived from human lysozyme, its radiolabeling with 68Ga and evaluation as an infection imaging PET probe. (2019) (0)
Preferred blood-brain transfer of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain (2007) (0)
Prediction of low grade glioma recurrence using dynamic [18F]-FET-PET (2013) (0)
Ga-68 labeled prostate specific membrane antigen ligand Glu-NH-CO-NH-Lys-(Ahx)-[HBED-CC] for detection of prostate cancer (2014) (0)
Early 18F Galacto-RGD uptake is associated with long-term LV remodeling after myocardial infarction in rat (2010) (0)
EO8 Initial experience with PSMA-radioguided surgery in prostate cancer patients (2014) (0)
Corrigendum: Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications (2014) (0)
18f-Rhpsma-7 Positron Emission Tomography (PET) for the Detection of Biochemical Recurrence after Primary Radiation Therapy of Prostate Cancer (2019) (0)
MP149MOLECULAR IMAGING OF THE CHEMOKINE RECEPTOR CXCR4 TO LOCALIZE SITES OF LEUKOCYTE ACCUMULATION DUE TO COMPLICATED URINARY TRACT INFECTION IN KIDNEY TRANSPLANTAT RECIPIENTS (2017) (0)
Development of a remote controlled synthesis apparatus for routine production of (S)-[11C]CGP 12388 (2001) (0)
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a head-to-head comparison with DOTATOC and FDG PET/CT (2016) (0)
Imaging of chemokine receptor 4 expression in neuroendocrine tumors in comparison to DOTATOC and FDG PET/CT (2016) (0)
68Ga-pentixafor PET/MRI in a rabbit model of atherosclerotic plaques (2016) (0)
EO6 Preoperative lymph node staging of intermediate and high-risk prostate cancer using whole body integrated PET/MR with a 68Gallium-labelled ligand of prostate-specific membrane antigen (2014) (0)
Clinical results of salvage PSMA-radioguided surgery in recurrent prostate cancer (2018) (0)
PD14-01 CLINICAL EXPERIENCE WITH LUTETIUM 177-LABELED PSMA-I&T FOR RADIOLIGAND THERAPY IN 100 CONSECUTIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2018) (0)
EVALUATION OF RECURRENT PROSTATE CANCER AFTER PRIMARY RADIATION THERAPY AS DEFINED BY PHOENIX CRITERIA BY 68GA‐PSMA PET/CT: PD61‐03 (2017) (0)
There Is a Place forDigoxin (2018) (0)
MP62-17 DIAGNOSTIC EFFICACY OF 18 F-RHPSMA-7.3 IMAGING FOR N-STAGING PATIENTS WITH HIGH-RISK PROSTATE CANCER (2020) (0)
PSMA-targeted18F-labeled Radiohybrid Inhibitors: Concept, preclinical evaluation and first proof of concept study in men (2019) (0)
Preoperative lymph node staging of intermediate and high-risk prostate cancer using whole body integrated PET / MR with a 68 Gallium-labelled ligand of prostate-specific membrane antigen (2014) (0)
Identification of CXCR4 Expression By Targeted PET/MR Imaging in Patients with Acute Myeloid Leukemia (AML) (2015) (0)
Evaluation of 68Ga-labeled RGD peptides for αvβ3 integrin detection in myocardial infarct (2012) (0)
Comparison of two different transgenic mouse models of Alzheimer’s disease regarding their suitability for amyloid-β plaque microPET imaging with [11C]PIB (2008) (0)
Subgroup analysis for the lung tumors only, showing a scatter plot of the voxel-by-voxel correlation of ADC and 18 F-FDG uptake. (2015) (0)
Fully automated zirconium-89 antibody labeling and purification (2019) (0)
Abstract 20112: Molecular Imaging of Chemokine Receptor Type 4 (CXCR4) Upregulation Independently Predicts Subsequent Contractile Dysfunction After Cardiac Ischemia in Mice (2017) (0)
18F-Galacto-RGD detects anti-inflammatory effect of dietary intervention on mouse atherosclerotic lesions (2009) (0)
Imaging of {alpha}v{beta}3 in human carotid plaques by [18F]galacto-RGD PET/CT (2008) (0)
In vivo imaging and quantification of CXCR4 expression in lung cancer subtypes using 68Ga-Pentixafor PET/CT and Flow cytometry analysis: A single center and First Asian Experience (2019) (0)
Glycated octreotide and octreotate analogues for specific and high-level targeting to medulloblastoma (2001) (0)
452 INVITED Imaging probes for αvβ3 and CXCR4 (2006) (0)
[68Ga]DOTA-RGD for the non-invasive determination of the {alpha}v{beta}3 integrin expression (2006) (0)
Imaging of integrin {alpha}5{beta}1 in post infarct myocardium using 68Ga-FR336 (2014) (0)
A DOTA-analog tetra-phosphinate chelator for preparation of tetrameric bioconjugates (2012) (0)
P063 Staging of biochemical recurrent prostate cancer after radical prostatectomy using 68Gallium-labelled ligand of prostate-specific membrane antigen PET/CT and PET/MRI (2014) (0)
Glycation of SST‐receptor‐agonists: Improvement of dynamic ligand trafficking of radiolabelled somatostatin agonists (2001) (0)
MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER (2015) (0)
Imaging of αvβ3 in human carotid plaques by [18F]galacto-RGD PET/CT (2008) (0)
In vivo PET imaging of {beta}-amyloid plaques in an APP/PS1 mouse model of Alzheimer's disease: Comparison of [18F]FIBT and [18F]Florbetaben with [11C]PiB (2012) (0)
Predictive value of initial 18FLT-uptake in patients with diffuse large B cell lymphoma (DLBCL) undergoing R-CHOP treatment (2010) (0)
IC-102-03 Assessment of cerebral hypometabolism and amyloid plaque load in semantic dementia and dementia of the Alzheimer type (2006) (0)
TRAP-based multimeric peptide conjugates with unprecedented 68Ga3+ complexation efficiency and excellent in vivo characteristics (2011) (0)
Abstract 2947: A Novel [F-18] labeled PET Tracer for the Characterization of Coronary Artery Disease: Preliminary Evaluation in a Coronary Occlusion Rat Model (2007) (0)
Molecular Imaging of Angiogenesis (2010) (0)
Abstract ED4-3: PET tracer for therapy monitoring (2010) (0)
Development of metabolically stabilized 11C-labeled 2-(4-aminophenyl)benzothiazols (BTAs) for imaging of amyloid plaques (2006) (0)
Radiation dosimetry for 177Lu-PSMA I&T therapy in metastatic prostate cancer: results for normal organs, tumor lesions and comparison between different cycles (2016) (0)
Relationship between the degree of water diffusivity and glucose metabolism, and their potential biological correlate. (2015) (0)
In-vivo imaging of proliferation in patients with mantle cell lymphoma and correlation with Ki-67 protein expression (2011) (0)
Correction: 18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases (2018) (0)
Automated and repetitive production of PET tracers with {micro}-fluidics: A "faster lab" (2008) (0)
Biological Evaluation of the Distinct Integrin Subtypes alpha v beta 3 and alpha 5 beta 1 via Surface Coating and PET Imaging (2011) (0)
Development of18F-labeled compounds for imaging of Aβ plaques by means of PET (2015) (0)
In vivo imaging of cerebral amyloid plaque load and glucose metabolism in semantic dementia and Alzheimer's disease (2006) (0)
Imaging chemokine receptor CXCR 4 in chronic infection of the bone with 68 Ga-Pentixafor-PET / CT – first insights . Running title : 68 Ga-Pentixafor-PET / CT in bone infection (2017) (0)
Diagnostic efficacy of 18F-rhPSMA7 positron emission tomography for lymph node staging in patients with high-risk primary prostate cancer (2019) (0)
Synthesis and evaluation of new compounds suitable for in vivo visualization of {beta}-amyloid plaques (2009) (0)
A new family of tacn derivatives for 64Cu and 68Ga chelation (2019) (0)
MP09-16 18F-RHPSMA7 POSITRON EMISSION TOMOGRAPHY FOR THE DETECTION OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY (2019) (0)
NOPO as a chelator for preparation of 68Ga-labeled monoconjugates (2012) (0)
Performance of MAP-Bayesian methods for managing loss of metabolite samples in PET ligand studies (2005) (0)
Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer. (2018) (0)
A-C. The tumors were divided into voxel rings starting from the periphery to the tumor center (A). (2015) (0)
Imaging inflammation crosstalk along the cardio-renal axis after acute myocardial infarction (2020) (0)
Nuclear Medicine and Biology (2013) (0)
Cover Feature: Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy (Chem. Eur. J. 3/2018) (2018) (0)
Uptake of [18F]-galacto-RGD, a PET tracer for imaging {alpha}v{beta}3 integrin, in mouse atherosclerotic plaques (2008) (0)
Recent progress in the field of αv-integrin antagonists (2002) (0)
A-D. Patient with a primary NSCLC of the left upper lobe infiltrating the chest wall (A: ADC map from DW-MRI). (2015) (0)
Comparison of [11C]choline and [18F]galacto-RGD as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hans‐jürgen Wester?

Hans‐jürgen Wester is affiliated with the following schools:

Technical University of Munich

Hans‐jürgen Wester's Academic­Influence.com Rankings

Why Is Hans‐jürgen Wester Influential?

Hans‐jürgen Wester's Published Works

Published Works

What Schools Are Affiliated With Hans‐jürgen Wester?

Hans‐jürgen Wester's AcademicInfluence.com Rankings